Skip to main navigation
logo

Investor Relations

  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Shareholder Services
    • Investor FAQs
    • Email Alerts
    • Contact IR
  • Videos

News Release Details

OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

Go Back
October 22, 2021
OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma.pdf 40.4 KB

Investor Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Contact IR

© 2022 Advaxis, Inc..     All rights reserved.

  • Facebook
  • Twitter
  • LinkedIn
  • Google+